findmyKOL

Mikkael Sekeres, MD, MSc

Enriched profile

Chief, Division of Hematology, and Professor of Medicine with Tenure, Department of Medicine, University of Miami Miller School of Medicine · Sylvester Comprehensive Cancer Center

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Miami, FL · Southeast · United StatesSpecialtyHematology / OncologyFocusAcute Myeloid Leukemia Research+4
Active KOLfindmyKOL type: EliteLatest publication2026Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Mikkael Sekeres is Chief, Division of Hematology, and Professor of Medicine with Tenure, Department of Medicine, University of Miami Miller School of Medicine at Sylvester Comprehensive Cancer Center. OpenAlex indexes 1,453 publications with 37,894 citations (h-index 92); ClinicalTrials.gov lists 10 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 16 Oct 2026

Mikkael A. Sekeres, MD, is Chief, Division of Hematology, and Professor of Medicine with Tenure, Department of Medicine, University of Miami Miller School of Medicine at Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Department of Medicine, Division of Hematology. The public record shows 1,453 publications with 37,894 citations (h-index 92), centered on Acute Myeloid Leukemia Research, Myeloproliferative Neoplasms: Diagnosis and Treatment, Chronic Myeloid Leukemia Treatments. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 22 companies.

  • Most recent indexed publication: 2026 · Leukemia
  • Top research focus: Acute Myeloid Leukemia Research
  • 10 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 22 companies

Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
MDS / MPN9 trialsLeukemia (AML/ALL/CML/CLL)5 trialsLeukemia, Myeloid, Acute2 trialsMyeloproliferative Disorders1 trialLeukemia, Erythroblastic, Acute1 trialCytopenia1 trial

Research focus

OpenAlex concept fingerprint
Acute Myeloid Leukemia ResearchMyeloproliferative Neoplasms: Diagnosis and TreatmentChronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia ResearchAcute Lymphoblastic Leukemia research

Drugs & molecules

across trials, industry payments and publications
Reblozylgeneric · LuspaterceptClinical trials1Industry payments2Publications2Vanflytageneric · QuizartinibClinical trials—Industry payments10Publications2AzacitidineClinical trials2Industry payments—Publications8LenalidomideClinical trials4Industry payments—Publications1Rytelogeneric · ImetelstatClinical trials—Industry payments1Publications1VorinostatClinical trials1Industry payments—Publications1Pyrukyndgeneric · MitapivatClinical trials—Industry payments6Publications—Xpoviogeneric · SelinexorClinical trials—Industry payments5Publications—ElriterceptClinical trials3Industry payments—Publications—Keytrudageneric · PembrolizumabClinical trials—Industry payments3Publications—Arsenic trioxideClinical trials2Industry payments—Publications—Elzonrisgeneric · TagraxofuspClinical trials—Industry payments2Publications—

Works with

trial sponsors and companies reporting payments
Daiichi Sankyo Inc.Clinical trials—Industry payments11AstraZeneca Pharmaceuticals LPClinical trials—Industry payments7Celgene CorporationClinical trials—Industry payments7Agios Pharmaceuticals, Inc.Clinical trials—Industry payments6Novartis Pharmaceuticals CorporationClinical trials—Industry payments6Karyopharm Therapeutics Inc.Clinical trials—Industry payments5Takeda Pharmaceuticals U.S.A., Inc.Clinical trials—Industry payments5E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments4Genmab U.S., Inc.Clinical trials—Industry payments4Merck Sharp & Dohme CorporationClinical trials—Industry payments3TakedaClinical trials3Industry payments—Eli Lilly and CompanyClinical trials—Industry payments2Gilead Sciences, Inc.Clinical trials—Industry payments2Mikkael Sekeres MDClinical trials2Industry payments—National Cancer Institute (NCI)Clinical trials2Industry payments—Stemline Therapeutics Inc.Clinical trials—Industry payments2Astellas Pharma US IncClinical trials—Industry payments1BeiGene USA, Inc.Clinical trials—Industry payments1Boehringer Ingelheim Pharmaceuticals, Inc.Clinical trials—Industry payments1Case Comprehensive Cancer CenterClinical trials1Industry payments—Geron CorporationClinical trials—Industry payments1GlaxoSmithKline, LLC.Clinical trials—Industry payments1Incyte CorporationClinical trials—Industry payments1MorphoSys, US Inc.Clinical trials—Industry payments1National Heart, Lung, and Blood Institute (NHLBI)Clinical trials1Industry payments—Secura Bio, Inc.Clinical trials—Industry payments1The Cleveland ClinicClinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,453publications

Distinct works indexed by OpenAlex, matched via ORCID; 39 in PubMed.

37,894citations

Total citations across indexed works.

92h-index

Hirsch index (OpenAlex). i10-index 401.

Clinical & industry

trials, payments and federal funding
10clinical trials

Investigator role on registered studies.

View trials ↓
22companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Public positions

sourced statements on record

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 16 Oct 2026

Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:

All 10 trial records: search, sort and filter.Explore →

Industry payments

Updated 16 Oct 2026

22 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 38 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    90.8%
    BCL-2 Inhibitor35.1%
    Venclexta100%
    Part D≥12 patients
    Kinase inhibitor29.8%
    Imatinib Mesylate69%Tasigna31%
    Part D<11 patients

    + 2 more classes in this area

  • Anti-infectives

    9.2%
    Fluoroquinolone Antibacterial9.2%
    Levofloxacin100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 16 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 39 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    Revised International Prognostic Scoring System for Myelodysplastic Syndromes
    3,145 citations2012
    doi.org ↗
  2. 02
    Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
    1,933 citations2015
    doi.org ↗
  3. 03
    Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
    1,514 citations2020
    doi.org ↗
  4. 04
    Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
    1,472 citations2017
    doi.org ↗
  5. 05
    Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
    1,415 citations2018
    doi.org ↗
All 1,453 cited works: search, sort and filter.Explore →

Network

Updated 16 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Jaroslaw P. Maciejewski554Rami S. Komrokji305Anjali S. Advani267Hetty E. Carraway265Aziz Nazha216Matt Kalaycio210Sudipto Mukherjee200Amy E. DeZern186Gail J. Roboz181Guillermo Garcia‐Manero181Alan F. List179Pierre Fenaux176David P. Steensma170Aaron T. Gerds168Bartlomiej Przychodzen165Valeria Visconte154Ramón V. Tiu144Hideki Makishima140Ronald Sobecks127Tomas Radivoyevitch127Uwe Platzbecker127Valeria Santini124Amer M. Zeidan123Eric Padron113Cassandra M. Hirsch106Michael R. Savona105Yogen Saunthararajah102Hagop M. Kantarjian93Bhumika J. Patel92Yasunobu Nagata88David A. Sallman82Vera Ademà77Harry P. Erba76Hassan Awada73Betty K. Hamilton69Yazan F. Madanat68Jeffrey E. Lancet66Torsten Haferlach66Teodora Kuzmanovic66Edward A. Copelan64

Online presence

Updated 16 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/mikkael-sekeres-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • LinkedIn

    linkedin.com/in/mikkael-sekeres-93a648231

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
  • Other

    mikkaelsekeres.com/about-me

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mikkaelsekeres.com ↗
  • X / Twitter

    x.com/mikkaelsekeres

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com ↗

Mentions by others

where others cite or feature them
  • Instagram

    instagram.com/sylvestercancer/p/C6rVuu7LGjo

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗
  • Facebook

    m.facebook.com/SylvesterCancer/videos/meet-dr-mikkael-a-sekeres-dr-sekeres-chief-of-hematology-at-sylvester-explains-h/345427397602383

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →m.facebook.com ↗
  • Apple Podcasts

    podcasts.apple.com/us/podcast/cancer-stories-the-art-of-oncology/id1365887382

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →podcasts.apple.com ↗
  • Facebook

    facebook.com/SylvesterCancer/posts/congratulations-to-mikkael-sekeres-md-ms-chief-of-the-division-of-hematology-at-/1253861903443258

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗
  • Facebook

    facebook.com/aamds/videos/do-you-want-a-second-opinion-about-your-conditiondr-mikkael-sekeres-describes-wh/1494944038080885

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗
  • ResearchGate

    researchgate.net/scientific-contributions/Mikkael-A-Sekeres-2173638462

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
  • YouTube

    youtube.com/shorts/s0XbdgogDbg

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
  • X / Twitter

    X (Twitter): @MikkaelSekeres

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com ↗
  • Mikkaelsekeres.com

    Personal author website: mikkaelsekeres.com

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mikkaelsekeres.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 16 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Chief

    Division of Hematology, Department of Medicine, University of Miami Miller School of Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.miami.edu ↗
  • Professor of Medicine with Tenure

    University of Miami Miller School of Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.miami.edu ↗
  • Chair

    ASH Treatment Guidelines for Older Adults with Acute Myeloid Leukemia (AML)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aamds.org ↗
  • Former Editor-in-Chief

    ASH Clinical News magazine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aamds.org ↗

Awards & honors

honors on the public record
  • Elected Councillor

    American Society of Hematology (ASH) Executive Committee, four-year term beginning after the 2025 ASH Annual Meeting

    2025
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →eurekalert.org ↗
  • Leadership in Science Award

    Aplastic Anemia and MDS International Foundation (AAMDSIF)

    2013
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aamds.org ↗

Secondary affiliations

appointments beyond the home institution
  • Former Professor of Medicine

    Director of the Leukemia Program, and Vice Chair for Clinical Research, Cleveland Clinic Taussig Cancer Institute

    2020
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aamds.org ↗
  • Physician Liaison in Hematology / co-Chair

    Medical Advisory Board, Aplastic Anemia and MDS International Foundation (AAMDSIF), since 2004

    2004
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aamds.org ↗
  • Member

    American Society of Clinical Oncology (ASCO)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aamds.org ↗
  • Member

    Southwest Oncology Group (SWOG), Leukemia Committee

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aamds.org ↗

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.